• Icon International Neuroendocrine Cancer Alliance

  • Mail: post@incalliance.org

Tag: PRRT

unnamed
CNETS Canada NET Research Priorities Survey Results

In March CNETS Canada reached out to the patient community through an online, anonymous survey to gather feedback and input on setting the research priorities for CNETS Canada sponsored grants for the next 2-3 years. 187 responses from across Canada were received with 75% of the replies from patients. One of the most significant findings…

Read More
NETRF
NETRF Works to Take PRRT to Next Level

The Neuroendocrine Tumor Research Foundation (NETRF) has invested more than $1.5 million in advancing a precision form of radiation therapy for NETs called Peptide Receptor Radionuclide Therapy (PRRT). Improving efficacy and safety Three NETRF-funded studies are looking at how existing approaches to PRRT can be improved to: Expand the number of patients able to benefit from PRRT…

Read More
npfcrop
NET Patient Foundation Reports Success in Treatment Availability in UK

For a couple of years now, the UK has struggled with NET treatments being unavailable, due to lack of NHS approval. The NPF is however delighted with the three positive outcomes it has received this month. Patients, healthcare professionals and industry groups have been working so hard to bring us back to a service where…

Read More
UFNZedit
Unicorn Foundation New Zealand Fundraising Waterfront Half Marathon

The Unicorn Foundation New Zealand has a growing team of keen walkers & runners who took part in the Waterfront Half Marathon on April 8, 2018 in Auckland, New Zealand. Team Unicorn Foundation New Zealand ran to help raise funds and awareness for the work of the organization, which supports and advocates for patients and…

Read More
unicornnzedit
PRRT One Step Closer to Being Funded for NET Patients in New Zealand

The Unicorn Foundation New Zealand has been verbally advised of the outcome of the recent Pharmac Pharmacology and Therapeutics Advisory Committee (PTAC) committee. They have agreed with the recommendation to fund PRRT for NET cancer patients in New Zealand! This is a hugely positive step forward, however there is still more work to be done…

Read More
netrf2edit
NET Research Foundation Awards Six Grants Totaling $1.85 Million to Expand Understanding of NETs

The Neuroendocrine Tumor Research Foundation (NETRF) awarded six new research grants totaling $1.85 million to leading academic institutions around the world. The goal of the funding is to improve current treatments for neuroendocrine tumors (NETs) “We are funding projects with the potential to be rapidly transitioned from bench to clinic because time is critical to…

Read More
IMG_3424
PRRT trials for pheo/para patients have begun at the National Cancer Institute in Washington, D.C.

The Pheo Para Alliance announced that PRRT trials for pheo/para patients have begun at the National Cancer Institute, a division of the National Institutes of Health in Washington, D.C. More information on this important clinical trial can be found here. The alliance, which was formed by the merger of the Pheo Para Alliance and the…

Read More
Unicorn Foundation New Zealand, PRRT, NET patients
Great news for NET cancer community in New Zealand

Unicorn Foundation New Zeleand happily announced on 21 November 2017 that they got the result from the Consumer Submission which was made earlier in August to Pharmac, the New Zealand government agency that decides which pharmaceuticals to publicly fund in New Zealand. The Cancer Treatments Sub-committee have recommended that PRRT be funded for patients with…

Read More
SiobhanConroy, Unicorn Foundation New Zealand
Unicorn Foundation New Zealand campaigns for government funding of PRRT for NET patients

Unicorn Foundation New Zealand and eight more cancer local organizations presented a manifesto to the Minister of Health, politicians and their health advisors in a campaign to encourage all political parties to work with the NGOS to help Kiwis receive improved cancer care, funding and access to treatment no matter where one lives in New…

Read More
CNETS India
CNETS India informs Alpha PRRT is now available for NET patients in India

CNETS India team is happy to share that two nuclear medicine centres in India have started Alpha PRRT for NET patients.  World over, many clinical trials have established the benefit of PRRT for metastatic NETs. Alpha PRRT uses the more powerful alpha particle emitting agents, Actinium 225 or Bismuth 213, in place of Lutetium 177…

Read More
Copyright © 2015 International Neuroendocrine Cancer Alliance. All right reserved.
Make a Donation
Paybal button